Nexgard Plus

Verify with FDA CVM →

42 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
42
Total Reports
1
Deaths Reported
240.0%
Death Rate

Active Ingredients

Nexgard Plus

Administration Routes

UnknownOral

Species Affected

Dog 41
Cat 1

Most Affected Breeds

Retriever - Labrador 8
Retriever - Golden 3
Bulldog - American 2
Dachshund (unspecified) 2
Shepherd Dog - Australian 2
Crossbred Canine/dog 2
Terrier - Yorkshire 2
Shih Tzu 2
Rottweiler 2
Terrier - Bull - Staffordshire 2

Most Reported Reactions

Lack of efficacy (endoparasite) - heartworm 10
Ataxia 5
Inappropriate urination 4
Lack of efficacy (bacteria) - Borrelia 3
Lack of efficacy - NOS 3
Medication error NOS 3
Vomiting 3
Abnormal radiograph finding 3
Bone and joint disorder NOS 3
Urinary tract infection 2
Grand mal seizure 2
Seizure NOS 2

Outcome Breakdown

Ongoing
36 (85.7%)
Recovered/Normal
4 (9.5%)
Outcome Unknown
1 (2.4%)
Euthanized
1 (2.4%)

Data Summary

Metric Value
Total adverse event reports 42
Reports involving death 1
Case-fatality rate (reported events) 240.0%
Distinct species in reports 2
Distinct breeds in reports 20
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Nexgard Plus Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 42 adverse event reports referencing Nexgard Plus, including 1 reports in which the animal died — a 240.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Nexgard Plus. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Nexgard Plus reports are Dog (41 reports), Cat (1 reports), with Dog accounting for the largest share. Within those species, Retriever - Labrador (8), Retriever - Golden (3), Bulldog - American (2) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Nexgard Plus are Lack of efficacy (endoparasite) - heartworm (10), Ataxia (5), Inappropriate urination (4), Lack of efficacy (bacteria) - Borrelia (3). Of the 42 reports with a coded outcome, Ongoing is the leading category at 85.7%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Nexgard Plus.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial